7 studies found for:    19106084 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting Cost-effectiveness of Genotype Guided Treatment With Antiplatelet Drugs in STEMI Patients: Optimization of Treatment
Conditions: Myocardial Infarction;   STEMI
Intervention: Genetic: CYP2C19 genotyping
2 Terminated Genotype Guided Comparison of Clopidogrel and Prasugrel Outcomes Study
Condition: Cardiovascular Disease
Intervention:
3 Recruiting Pharmacodynamic Study on Efficacy of Clopidogrel With St. John's Wort
Condition: Acute Coronary Syndrome
Interventions: Drug: Placebo;   Drug: St. Johns Wort
4 Completed ReAssessment of Anti-Platelet Therapy Using an InDividualized Strategy Based on GENetic Evaluation
Conditions: Stable Coronary Artery Disease;   Acute Coronary Syndrome;   Percutaneous Coronary Intervention
Intervention: Genetic: Point-of-care genetic screening with subsequent prasugrel administration to CYP2C19*2 carriers
5 Completed Pharmacogenetic Approach to Anti-platelet Therapy for the Treatment of ST-segment Elevation Myocardial Infarction (STEMI)
Condition: STEMI
Interventions: Genetic: Point-of-Care Genetic Testing;   Drug: Prasugrel
6 Completed Adjunctive Cilostazol Versus High Maintenance-dose ClopidogrEL in Acute Myocardial Infarction (AMI) Patients According to CYP2C19 Polymorphism
Condition: Myocardial Infarction
Interventions: Drug: cilostazol;   Drug: clopidogrel (Plavix);   Genetic: CYP2C19;   Drug: aspirin (Acetylsalicylic acid)
7 Completed
Has Results
A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention
Conditions: Coronary Arteriosclerosis;   Acute Coronary Syndromes
Interventions: Drug: Prasugrel;   Drug: Clopidogrel

Indicates status has not been verified in more than two years